At present, pharmaceutical listed companies have issued three-quarter earnings reports one after another, in which the chemical raw material drug sector has performed well! In 2018Q3, the business income of the chemical raw material drug sector reached 80.499 billion yuan, an increase of 26.36% over the same period of last year, and net profit of returned mother reached 9.842 billion yuan, an increase of 56.82% over the same period of last year. In recent years, the environmental protection department has been under strict supervision, the supply side has been tightened, the price of raw materials has risen correspondingly, and the business income has continued to rise year-on-year. Since the winter of 2017, the pressure of environmental protection has further increased, and the prices of major APIs have reached new heights, bringing about high growth in performance. In the second half of 2018, the price of chemical raw materials continued to rise since the beginning of the year, and many vitamin manufacturers disclosed their good results in advance. Specifically, the "vitamin family" in chemical APIs is a big winner, either in single season or in the first three quarters.
As the upstream link of pharmaceutical industry, the development of API industry is inseparable from, or even consistent with, the development of pharmaceutical industry. In the past two years, the price of vitamin APIs has risen sharply due to the influence of environmental protection and the resistance of raw material drug giants such as Basf, and even a lot of APIs are out of supply. Among them, vitamin A and vitamin E were the most affected by BASF event.
In addition to VE, VA and VD3 prices also let the leading enterprises achieve a good harvest. Jin Dawei, who is engaged in the raw materials of food nutrition fortifier industry, said that the company's business income in the first three quarters was 2.079 billion yuan, an increase of 51.62% over the same period last year. The main reasons are that the sales revenue of VA increased by 458 million yuan, VD3 increased by 0.41 billion yuan, coenzyme Q10 increased by 0.118 billion yuan and dietary supplements increased by 0.78 billion yuan. And the increase in income resulting from the increase in the scope of consolidated statements. The company's net profit in the first three quarters increased by 170.88% over the same period last year. Jin Dawei expects net profit of 700 million yuan to 800 million yuan in 2018, with a range of 47.66% to 68.76%.
In response to the above phenomena, market analysts believe that since the first half of this year, the price of multi-vitamin products has been rising due to the price increase of vitamin raw materials and the impact of environmental productivity. Although the prices of some products have stabilized in the second half of the year, many listed companies have established the main tone of their performance growth in 2018, benefiting from the high prosperity brought about by the rise in vitamin prices.